Ann: Annual Report to shareholders, page-35

Hi Titans,

If @FXm has been dragged into this with the other two & my comments are wrong, then I am sincerely sorry about that, but nothing else.

I have no problem with DTs being here, some give some great insights & I enjoy reading a lot of their posts & giving likes, it’s not an “us & them” situation, we co-exist & it’s not like some of us don’t participate in trading, instead of sitting like statues.

What I have a big issue with, is the DELIBERATE & repeated posting of misinformation & downright mistruths, for entirely selfish reasons. I hope no one listened & hit the sell button in the lows. I have a SOH, & can take some banter, but it’s just a bit beyond that. The ignore button is the best option.

We have some amazing things happening here, & I’m guessing this behaviour may continue. Today’s topic will probably be on a CR for trials & our large share registry.

So just getting in early here: BVF (USA) stumped up for Xanadu trial & still a major SH, the remainder taken up by SH, myself included (average is way down from those days).

Now that we have so much data on board from multiple trials & some amazing results from Xanahes with efficacy and safety, I think this time around we may be looking at M&A at least with a milestones deal to run trials. It’s big news.

Biogen’s success is only going to spur on interest in the AD space, & we are somewhat de-risked here now on results, which was also reflected in recent stock analysis.

GLTAH including the DTs